Journals / MN Oftalmoloji / 2013 / Cilt: 20 - Sayı: 1

Evaluation of the effectiveness on central corneal thickness and visual field of monotherapy with either bimatoprost or travoprost in patients who after latanoprost therapy in primary open angle glaucoma

Latanoprost tedavisi alan primer açık açılı glokom olgularında travoprost ya da bimatoprost monoterapisine geçişle görme alanı ve santral kornea kalınlığı üzerine oluşan etkinliğin değerlendirilmesi

Pages
15–19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The difference average MD values in visual field at the end of six months was not statistically significant in both groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: This prospective study aimed to evaluate the efficacy of monotherapy with either bimatoprost or travoprost in patients who after tanoprost therapy in primary open angle glaucoma (POAG).
📊
Key Findings & Data:Material and Method: Between March 2009 and March 2010, 40 patients with POAG receiving therapy with topical latanoprost at Gaziantep University Hospital, Department of Ophthalmology were chosen to participate in this study.
💡
Conclusion & Impact:The difference average MD values in visual field at the end of six months was not statistically significant in both groups.
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: This prospective study aimed to evaluate the efficacy of monotherapy with either bimatoprost or travoprost in patients who after tanoprost therapy in primary open angle glaucoma (POAG). Material and Method: Between March 2009 and March 2010, 40 patients with POAG receiving therapy with topical latanoprost at Gaziantep University Hospital, Department of Ophthalmology were chosen to participate in this study. Latanoprost therapy was stopped in all patients, 20 were chosen to receive monotherapy with bimatoprost and 20 were chosen to receive monotherapy with travoprost. Patients have observed for 6 months. Results: The initial corneal thickness was measured 552.80±28.45 microns in bimatoprost group, 558.85±24.59 microns in travoprost group. At the end of the sixth month, ıt was found 551,75±27,89 microns in the first group and 557.25±23.34 microns in the second group. Average MD was found to be 3.63±3.66 dB at the beginning, 3.64±3.59 dB at the end of the sixth month in patients treated with bimatoprost. Average MD was found to be 4.16±4.49 dB at the beginning, 4.11±4.18 dB at the end of the sixth month in group of patients treated with travoprost Conclusion: As a result, reduction in corneal thickness from baseline was too small in two groups at six month. However, this reduction was not statistically significant in both groups. The difference average MD values in visual field at the end of six months was not statistically significant in both groups.

Özet

Amaç: Bu çalışmamızın amacı, latanoprost tedavisi alan primer açık açılı glokom (PAAG) hastalarında, bu ilacı kesip prostoglandin olan travoprost ya da prostamid olan bimatoprosta geçişle oluşan görme alanı ve kornea kalınlığı gibi değişiklikleri incelemek. Gereç ve Yöntem: Mart 2009 - Mart 2010 tarihleri arasında Gaziantep Üniversitesi Tıp Fa kültesi Göz Hastalıkları Ana Bilim Dalı’nda topikal latanoprost monoterapisi ile takipte olan 40 primer açık açılı glokom hastası alındı. 40 PAAG olgusunun latanoprost tedavisi kesildi. Hastaların 20’sinde bimatoprost, 20’sinde ise travoprost monoterapisi şeklinde ilaç değişimi yapıldı. Hastalar 6 ay süre ile takip edildi. Bulgular: Bimatoprost grubunda başlangıç korneal kalınlık 552,80±28,45 mikron olarak, travoprost grubunda 558,85±24,59 mikron olarak ölçüldü. Altıncı ayın sonunda birinci grupta 551,75±27,89 mikron, ikinci grupta 557.25±23.34 mikron olarak bulundu. Bimatoprost kullanan hastalarda başlangıçta ortalama mean deviyasyon (MD) 3,63±3,66 dB, altıncı ayın sonunda ise 3,64±3,59 dB olarak bulundu. Travoprost kullanan grupta ise başlangıçta ortalama MD 4,16±4,49 dB, altıncı ayın sonunda 4,11±4,18 dB olarak bulundu. Sonuç: Sonuç olarak iki grupta da altıncı ay kornea kalınlığında başlangıca göre çok küçük düzeyde bir azalma görüldü. Fakat bu azalma her iki grupta da istatistiki olarak anlamlı bulunmadı. Her iki grupta da başlangıç ve 6. ay ortalama MD değerleri arasında oluşan fark istatistiksel olarak anlamlı değildi

🔖

Cite This Article

KOÇLUK, Y., GÜNGÖR, K., SAYGILI, O., BEKİR, N. A. (2013). Evaluation of the effectiveness on central corneal thickness and visual field of monotherapy with either bimatoprost or travoprost in patients who after latanoprost therapy in primary open angle glaucoma. MN Oftalmoloji, Cilt: 20 - Sayı: 1, 15–19. https://ajindex.com/articles/295708

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Kaufman PL, Mittag TW. Medical therapy of glaucoma. Kaufman PL, Mittag TW: Glaucoma, in Podos SM, Yanoff M (ed): Textbook of Ophthalmology, Mosby, London 1994;93-7
  2. Hoskins Jr. HD, Kass M. Cholinergic drugs, Becker Shaffer’s. Diagnosis and threrapy of the Glaucomas, Klein EA, Sixth Ed. the c.v. Mosby Company, St. Louis, Toronto, Baltimore 1989; 420-32
  3. Vogel R, Crick RP, Newson RB, Shipley M, Blackmore H, Bulpitt CJ. Association between intraocular pressure and loss of visual field in chronic simple glaucoma. British J Ophthalmol 1990;4:3-6
  4. Turaçlı E: Prostaglandin analogları. Glokom 2003;3:176-8
  5. Bito LZ. A physiologic approach to the development of new drugs for glaucoma. Ophthalmol Clin N Am 1989;2:65-76
  6. Curan MP. Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging 2009;26: 1049-71
  7. Philippe D, David C, Anthony R. Travoprost in the management of open angle glaucoma and ocular hypertension. Clin Ophthalmol 2007;1:11-24
  8. McKee HD, Gupta MS, Ahad MA. First-choice treatment preferences for primary open-angle glaucoma in the United Kingdom. Eye 2005;19:923-4
  9. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003; 135:55-63
  10. Simmons ST, Dirks MS, Noecker RJ. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. Adv Ther 2004;21:247-62
  11. Denis P, Lafuma A, Khoshnood B, et al. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin 2007;23:601-8
  12. Maul E, Carrasco FG, Costa VP, et al. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Clin Ther 2007;29:1915-23
  13. The AGIS Investigators. The advanced glaucoma intervention study (AGIS) 7: the relationship between control of intra ocular pressure and visuel field deterioration. Am J Ophthalmol 2000;130:429-40
  14. Mao L, Steward W, Shield M. Correlation between intra ocular pressure control and progressive glaucomatous damage in primary open angle glaucoma. Am J Ophthalmol 1991; 111:51-5
  15. J.P. Nordmann, C. LePen, H. Lilliu et. al. Estimating the Long- Term Visual F